Parkinson's Disease Sleep Disorder Treatment Companies
Overview
flowchart TD
companies_pd_sleep_disorder_tr["PD Sleep Disorder Treatment Companies"]
style companies_pd_sleep_disorder_tr fill:#4fc3f7,stroke:#333,color:#000
companies_pd_sleep_d_0["Market Landscape"]
companies_pd_sleep_disorder_tr -->|"includes"| companies_pd_sleep_d_0
style companies_pd_sleep_d_0 fill:#81c784,stroke:#333,color:#000
companies_pd_sleep_d_1["Unmet Need"]
companies_pd_sleep_disorder_tr -->|"includes"| companies_pd_sleep_d_1
style companies_pd_sleep_d_1 fill:#ef5350,stroke:#333,color:#000
companies_pd_sleep_d_2["Target Product Profile"]
companies_pd_sleep_disorder_tr -->|"includes"| companies_pd_sleep_d_2
style companies_pd_sleep_d_2 fill:#ffd54f,stroke:#333,color:#000
companies_pd_sleep_d_3["Companies in Development"]
companies_pd_sleep_disorder_tr -->|"includes"| companies_pd_sleep_d_3
style companies_pd_sleep_d_3 fill:#ce93d8,stroke:#333,color:#000
companies_pd_sleep_d_4["Idorsia Pharmaceuticals"]
companies_pd_sleep_disorder_tr -->|"includes"| companies_pd_sleep_d_4
style companies_pd_sleep_d_4 fill:#4fc3f7,stroke:#333,color:#000
companies_pd_sleep_d_5["Sunovion"]
companies_pd_sleep_disorder_tr -->|"includes"| companies_pd_sleep_d_5
style companies_pd_sleep_d_5 fill:#81c784,stroke:#333,color:#000
...Parkinson's Disease Sleep Disorder Treatment Companies
Overview
Mermaid diagram (expand to render)
Sleep disorders are among the most common and disabling non-motor symptoms of Parkinson's disease, affecting up to 90% of patients. REM sleep behavior disorder (RBD) is particularly significant as it serves as a prodromal marker of synucleinopathies, with approximately 80-90% of idiopathic RBD patients eventually developing Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy["@postuma2019"].
Despite the high prevalence and clinical significance, there are currently no FDA-approved treatments specifically for RBD in Parkinson's disease. Current management relies on off-label pharmacological approaches and emerging investigational therapies.
This page catalogs companies developing treatments for sleep disorders in Parkinson's disease, with a focus on REM sleep behavior disorder.
Market Landscape
Unmet Need
- No approved RBD therapies: RBD remains an indication with no approved pharmacological treatments
- Off-label use: Current standard of care uses clonazepam (benzodiazepine) and melatonin, neither approved for RBD
- Large patient population: Estimated 50 million people worldwide have RBD, with 50-90% progressing to neurodegenerative disease
- Neurodegeneration link: RBD represents a critical window for neuroprotective intervention
Target Product Profile
Ideal RBD treatments would:
- Reduce or eliminate REM sleep without atonia
- Improve sleep quality and reduce injury risk
- Potentially modify neurodegeneration course
- Have favorable safety profile given chronic use needs
Companies in Development
Idorsia Pharmaceuticals
Location: Allschwil, Switzerland
Website: [idorsia.com](https://www.idorsia.com)
Pipeline:
| Drug | Indication | Status | Mechanism |
|------|------------|--------|-----------|
| Daridorexant | Insomnia | Approved (US/EU) | Dual orexin receptor antagonist |
Idorsia developed daridorexant (QUVIVIQ), approved for insomnia disorder. While not specifically developed for RBD, orexin receptor antagonists may have potential in RBD by modulating sleep architecture. The company has CNS expertise from its Actelion heritage and could potentially pursue RBD indications[@daridorexant-approval].
Sunovion
Location: Marlborough, Massachusetts, USA
Website: [sunovion.com](https://www.sunovion.com)
Pipeline:
| Drug | Indication | Status | Mechanism |
|------|------------|--------|-----------|
| Dasolampanel | Insomnia | Phase 2 | AMPA receptor antagonist |
Sunovion (part of Sumitomo Pharma) has developing therapies for sleep disorders. Their expertise in CNS disorders could translate to RBD drug development.
Empatica
Location: Boston, Massachusetts, USA
Website: [empatica.com](https://www.empatica.com)
Focus: Digital health wearables for sleep monitoring
Empatica manufactures the EmbracePlus and other wearables capable of detecting sleep stages, movements during sleep, and potential RBD episodes. While not a therapeutic company per se, their technology is crucial for:
- RBD diagnosis support
- Treatment response monitoring
- Clinical trial endpoints
Oura
Location: Oulu, Finland
Website: [ouraring.com](https://ouraring.com)
Focus: Sleep tracking and health monitoring
Oura Ring and associated platforms provide sleep staging and movement tracking. Similar to Empatica, they provide important monitoring capabilities for RBD clinical trials.
Cereve (Medtronic)
Location: Minneapolis, Minnesota, USA
Website: [medtronic.com](https://www.medtronic.com)
Focus: Sleep disorder devices
Cereve, acquired by Medtronic, develops CPAP and other sleep disorder devices. Their expertise in sleep medicine could extend to neurodegenerative disease-related sleep disorders.
Off-Label Treatments (Current Standard of Care)
While not specifically approved for RBD, these compounds are used off-label:
Clonazepam
- Class: Benzodiazepine
- Dose: 0.25-1.0 mg at bedtime
- Efficacy: 50-80% response rate
- Limitations: Sedation, worsening of sleep apnea, falls risk
Melatonin
- Class: Hormone
- Dose: 3-12 mg at bedtime
- Efficacy: 50-70% response rate
- Advantages: Better safety profile than clonazepam
- Limitations: Variable response
Other Agents
- Pramipexole: Dopamine agonist (mixed results)
- Clonidine: Alpha-2 agonist
- trazodone: Antidepressant with sedating properties
Clinical Trial Landscape
Current clinical trials targeting sleep disorders in PD include various interventional and observational studies. See [Parkinson's Disease Clinical Trials](/clinical-trials/parkinsons-disease) for a comprehensive list.
Research and Academic Groups
International RBD Study Group
A consortium of researchers conducting longitudinal studies on RBD and neurodegenerative disease progression. Key studies include:
- North American Prodomal Synucleinopathy Consortium (NAPS)
- European RBD Study Group
Michael J. Fox Foundation
The MJFF funds significant research into sleep disorders in PD, including:
- Biomarker development for RBD
- Neuroprotective trial design for prodromal RBD
- Technology for RBD monitoring
Future Directions
Emerging Targets
Orexin system modulation: Orexin receptor antagonists may reduce REM sleep without atonia
GABAergic agents: Targeting specific GABA receptors in REM sleep control
Alpha-synuclein aggregation inhibitors: May address underlying neurodegeneration
Neuroprotective agents: Early intervention in prodromal RBDDiagnostic Partnerships
Companies developing sleep technologies are crucial partners for therapeutic developers:
- Wearable data for patient identification
- Digital endpoints for clinical trials
- Remote monitoring capabilities
Related Pages
- [REM Sleep Behavior Disorder](/diseases/rem-sleep-behavior-disorder)
- [Sleep Disorders in Neurodegeneration](/diseases/sleep-disorders-neurodegeneration)](/diseases/neurodegeneration)
- [Parkinson's Disease Non-Motor Symptoms](/diseases/parkinsons-disease)](/proteins/parkin)
- [PD Autonomic Dysfunction Treatments](/companies/pd-autonomic-dysfunction-treatments)
References
[Postuma RB, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder (2019)](https://doi.org/10.1093/brain/awz030)
[Daridorexant (QUVIVIQ) FDA Approval (2022)](https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals)
[Idorsia Pipeline Overview](https://www.idorsia.com/pipeline)
[Hogl B, et al. Idiopathic REM sleep behaviour disorder and neurodegeneration (2018)](https://doi.org/10.1038/s41582-017-0001-1)Pathway Diagram
The following diagram shows the key molecular relationships involving PD Sleep Disorder Treatment Companies discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)